English
Report issue

Covid GambitCOVID
COVID Price
N/A

Arthur says governments choose gold because it protects political power, while individuals choose Bitcoin for freedom and self‑custody
Arthur Hayes is just watching governments do what they’ve always done: choose control over freedom, paper over truth with printed bills, and make d...
Nov 8, 2025
4 min read
by CryptoPolitan

Pfizer clinches $10 billion Metsera deal, outbidding Novo Nordisk
Pfizer acquires Metsera for $10 billion, cementing their new obesity treatment strategy. The purchase concludes a weeklong bidding frenzy between t...
Nov 8, 2025
3 min read
by Invezz

XRP retreats despite big announcements out of Ripple’s Swell conference
XRP extended its November-start price decline on Tuesday, falling more than 9% in the aftermath of Ripple’s annual Swell conference in New York.
Nov 8, 2025
3 min read
by CryptoPolitan

My First Bitcoin Goes Global, Will Empower Educators Worldwide
Bitcoin Magazine
My First Bitcoin Goes Global, Will Empower Educators Worldwide
My First Bitcoin, the pioneering Bitcoin education project from El...
Nov 7, 2025
3 min read
by Bitcoin Magazine

Air Europa repays €475M state loan early as Turkish Airlines secures 26% stake
Spanish carrier Air Europa has repaid in advance a €475 million ($505 million) loan granted by Spain’s Strategic Companies Solvency Support Fund (F...
Nov 6, 2025
2 min read
by Invezz

Breaking down “Zohranomics,” NYC mayor Zohran Mamdani’s policy doctrine
Zohran Mamdani plans to fund universal child care, affordable housing, and a possible rent freeze by raising taxes on millionaires and corporations.
Nov 6, 2025
4 min read
by CryptoPolitan

Ethereum Adoption Accelerates: UBS Powers Live Fund Transactions On-Chain — What This Means
Swiss banking giant UBS has taken a major step toward institutional blockchain by completing its first live tokenized fund transaction on the Ether...
Nov 5, 2025
2 min read
by NewsBTC

Sarepta Therapeutics shares plunge after disappointing trial data
Sarepta Therapeutics Inc. shares plunged 37% on Tuesday after the biotechnology company reported disappointing trial results for two of its treatme...
Nov 4, 2025
3 min read
by Invezz

